BioPorto Diagnostics Inc.

When it comes to assessing kidney damage, clinicians now have an opportunity to know earlier to manage better with confidence.

Introducing ProNephro AKI™ (NGAL), the first US FDA-cleared biomarker for pediatric Acute Kidney Injury (AKI). ProNephro AKI (NGAL) is designed to help doctors identify patients aged 3 months through 21 years at risk of developing, or having persistent, moderate-to-severe AKI within 48-72 hours in the intensive care unit (ICU). Unlike serum creatinine, a muscle by-product that is the current standard of care but slow to rise in AKI, NGAL is a direct real-time marker of kidney cell damage and can potentially detect AKI days earlier than serum creatinine.

Visit booth 906 to learn how to use NGAL with serum creatine and cystatin C.